Worldwide breast cancer is the most frequently diagnosed cancer in woman. The majority, ∼70%, express the oestrogen receptor (ER). Oestrogen receptor-positive (ER+) disease has historically been perceived as the 'lesser of two evils\', yet many women with ER+ breast cancer still succumb to their disease. Breast cancer is responsible for over 10 000 deaths each year in the United Kingdom (http: //[www.cancerresearchuk.org](http://www.cancerresearchuk.org)) and remains the leading cause of cancer deaths among females in less developed countries ([@bib23]). The advent of gene expressing profiling and multiparametric assays has brought to the fore that ER+ breast cancer is a heterogeneous disease and highlights the importance of targeted individual treatment selection ([@bib20]; [@bib7]). For most of the world, these validated methods to stratify risk and guide treatment decisions are too expensive and subsequently not routinely available. As recognised by the St Gallen conference, surrogate markers or less expensive pathology tests may provide valuable information in such countries ([@bib4]).

Semiquantitative immunohistochemistry (IHC) is a near-universal method of tumour hormone receptor (ER and progesterone receptor, PR) testing. Tumour ER expression is a powerful predictor of response to endocrine therapy and its value is undisputed. Until recently, the biological role of PR was less well defined and it was considered a biomarker of ER function ([@bib13]). Oestrogen receptor-positive/progesterone receptor-positive (PR+) tumours are associated with better clinical outcome ([@bib24]; [@bib3]; [@bib21]); however, the underlying mechanism responsible for this was poorly understood. Recent, defining work has now elucidated that PR redirects where ER binds to chromatin and acts as a proliferative brake in ER+ breast cancer ([@bib15]). This highlights the role of functional crosstalk between both the ER and PR ([@bib15]) and underlines the value of both ER and PR testing in breast cancer.

In this study, we hypothesised that semiquantitative IHC ER and PR scores together may represent a surrogate 'snap shot\' of functional hormone receptor crosstalk. We therefore analysed the ER and PR together as a combined endocrine receptor (CER) to test if this would be more informative of outcome than either factor independently. We report that the CER is a better predictor of outcome than either the ER or PR, and the CER is an independent significant prognostic factor. The results were validated in a separate cohort of breast cancer patients.

Patients and methods
====================

Derivation study patient population
-----------------------------------

One thousand seven hundred and eleven female patients were diagnosed with primary operable invasive breast cancer (symptomatic and screen detected) between October 1995 and September 1998 in Greater Glasgow NHS hospitals. The Greater Glasgow Breast Cancer (GGBC) database contains pathological, treatment and follow-up details for these patients. Original pathology report included % tumour cells staining for ER. Progesterone receptor was not routinely tested during this period. Tumour samples were centrally reanalysed for 557 patients, randomly selected from the 1711 patients (33%) ([Supplementary Figure 1A](#sup1){ref-type="supplementary-material"}). All patients in this cohort received tamoxifen monotherapy for 5 years except for two whose prescribed endocrine agent was not documented as they were enrolled in the ATAC study. The Research Ethics Committee of North Glasgow University Hospital approved the collection of patient data and use of human tissue in this study.

Tissue microarray construction and IHC
--------------------------------------

We have previously described the method for the tissue microarray (TMA) construction using formalin-fixed paraffin-embedded tissue, taken at the time of surgical resection ([@bib16], [@bib17]). Triplicate TMA were constructed to avoid heterogeneity of PR staining ([@bib16]). The IHC for ER, PR and HER2 was performed as we described previously ([@bib16], [@bib17]) applying protocols established in the CPA-accredited diagnostic pathology laboratory, Glasgow Royal Infirmary with appropriate positive and negative controls.

IHC scoring
-----------

Tumour Allred ER and PR scores were scored as we have previously reported ([@bib16]). A cutoff to define receptor positivity for ER and PR was an Allred score ⩾3, the internationally accepted cutoff. High scores were defined as Allred 6--8, and low scores as Allred 3--5. Representative examples of ER and PR staining for each scoring category are shown in [Supplementary Figure 2](#sup1){ref-type="supplementary-material"}. Human epidermal growth factor receptor 2 membrane staining was scored as described previously ([@bib17]).

Combined endocrine receptor
---------------------------

The Allred ER and PR scores were reclassified. A score of 0 was assigned to an Allred score of \<3, 1 assigned to Allred scores 3--5 and 2 assigned to Allred scores 6--8. The CER was calculated as the average of the reclassified ER and PR scores. Combined endocrine receptor 0 represents negative endocrine receptor status, CER 0.5--1.5 represents impaired endocrine receptor status (CER impaired) and CER 2 represents high endocrine receptor status (CER high).

Validation study patient population
-----------------------------------

The validation cohort of patients consisted of a consecutive series of new diagnosed early invasive female breast cancer patients presenting at two Greater Glasgow Hospitals between January 2008 and January 2009 ([Supplementary Figure 1B](#sup1){ref-type="supplementary-material"}). The Caldicott Guardian granted permission for the use of patient data. All patients underwent curative surgery and adjuvant treatment prescriptions as per national guidelines (SIGN, 2007) were discussed at a postoperative multidisciplinary meeting. Oestrogen receptor and PR IHC Allred scores for this cohort were obtained from routine pathology records.

Follow-up
---------

Follow-up data was confirmed with the registrar general and patient case records for the derivation study patient population included survival status (alive, death other cause and breast cancer-specific death) and documentation of date and site of recurrence (none, local, regional, distant). For patients who died, the date of death was recorded; all deaths not attributable to breast cancer were censored at the date of death. The primary outcomes in this analysis were time from definitive surgery to breast cancer-specific death and time to recurrence. In addition, early 5-year disease-free survival (DFS) was analysed by censoring events at 5 years. Disease-free survival was defined as alive and well with no documented local, regional or distant breast cancer recurrence or breast cancer-specific death. Accordingly, the end points were breast cancer-specific survival (BCSS) and DFS at 5 years.

The validation study patient population follow-up was confirmed using electronic case records. For every patient, details of definitive surgery date and most recent clinical review date were collected to calculate time to outcome. Clinical review included either breast surgery follow-up clinic or oncology follow-up clinic. For patients who died, the date of death was recorded; all deaths not attributable to breast cancer were censored at the date of death. Patient status at most recent review date was recorded (alive and well, documented local, regional or distant breast cancer recurrence or breast cancer-specific death). The end point was DFS.

Statistical analysis
--------------------

Statistical analysis was carried out using SPSS version 22 (IBM, New York, NY, USA). Univariate survival analysis was performed using Kaplan--Meier method analysed by the log-rank test. Calculation of hazard ratios (HRs) for both univariate and multivariate analysis was performed using Cox\'s proportional-hazards model; a stepwise backward procedure was used to derive a final model of variables that had a significant independent relationship with patient outcome.

Results
=======

Derivation study population
---------------------------

A total of 1711 patients presented with operable invasive breast cancer from October 1995 to September 1998. Five hundred and fifty-seven patient tumour samples were randomly selected for TMA construction and centrally tested for ER and PR. Male breast cancers were excluded because of their biological heterogeneity. Accurate follow-up data and tumour Allred scores for ER and PR were available for 90% (*n*=503) patients. Sixty-three per cent (*n*=319) were ER+ and 42% (*n*=210) were ER+/PR+. Patient and tumour characteristics are detailed in [Table 1](#tbl1){ref-type="table"}. Median follow-up was 12.7 years, 61% (*n*=305) patients were alive, 20% (*n*=102) had died as a result of breast cancer and 19% (*n*=96) had died from other causes. At 5 years, 16% (*n*=82) had a breast cancer-specific event.

CER scores (0--2)
-----------------

Combined endocrine receptor score (0, 0.5, 1, 1.5, 2) survival analysis confirmed the selected cutoffs ([Figure 1](#fig1){ref-type="fig"}) defining the classification of negative (CER 0), impaired (CER 0.5--1.5) and high (CER2). Combined endocrine receptor 0 (HR 6.915; CI: 3.131--15.264; *P*=0.000002), CER 0.5 (HR 3.418; CI: 1.085--10.771; *P*=0.036), CER 1 (HR 2.617; CI: 1.044--6.560; *P*=0.040) and CER 1.5 (HR 3.031; CI: 1.099--8.360; *P*=0.032) with CER 2 as the indicator category.

Redistribution of endocrine response using the CER compared with ER
-------------------------------------------------------------------

Of the 319 ER+ patients, 263 patients had an Allred ER high (6--8), when the CER was applied, and 46% (*n*=121) of these patients were reclassified as impaired. In addition, 6% (*n*=12) of ER− were reclassified as CER impaired ([Table 1](#tbl1){ref-type="table"}).

CER and patient outcome
-----------------------

The CER classification resulted in a statistically significant difference in both early 5-year DFS and BCSS between negative, impaired and high categories ([Figure 2A and D](#fig2){ref-type="fig"}). No statistical difference was demonstrated between ER high and low ([Figure 2B and E](#fig2){ref-type="fig"}) or PR− and low ([Figure 2C and F](#fig2){ref-type="fig"}).

Multivariate analysis
---------------------

Survival analysis confirmed that tumour grade, tumour size and lymph node (LN) (0 nodes positive, 1--3 nodes positive and \>3 nodes positive) and HER2 positivity were all predictive of prognosis (data not shown).

The CER was a more powerful predictor of 5-year DFS and BCSS than either the ER or PR alone. In multivariate analysis that included ER, PR and CER, only the CER remained an independent prognostic variable for 5-year DFS (HR 0.393; CI: 0.283--0.548; *P*=0.00001) and BCSS (HR 0.553; CI: 0.423--0.722; *P*=2.506 × 10^−8^). In multivariate analysis that included grade, LN, tumour size category and HER2 status, CER impaired and negative were independent prognostic variables with CER high as the indicator category for 5-year DFS ([Table 2](#tbl2){ref-type="table"}). In terms of BCSS for the entire cohort, impaired CER was not statistically significant when analysed as a categorical variable ([Table 2](#tbl2){ref-type="table"}).

In contrast in subgroup analysis performed in ER+ patients (*n*=319), therefore excluding CER-negative patients, impaired CER was an independent marker of poor outcome for 5-years DFS and BCSS ([Table 2](#tbl2){ref-type="table"}) in multivariate analysis that included grade, LN, tumour size, HER2 status and PR status. Importantly, for 5-year DFS, impaired CER was a better predictor of outcome than PR status, tumour size and tumour grade ([Table 2](#tbl2){ref-type="table"}).

Validation study population
---------------------------

Validation of the prognostic power of the CER was performed in 455 patients diagnosed with early invasive operable breast cancer between January 2008 and January 2009. Patient and tumour characteristics are detailed in [Table 3](#tbl3){ref-type="table"}.

There were notable differences between the study cohorts. The validation cohort had fewer patients with ER− breast cancer and PR− breast cancer. As expected with a more recent cohort, the majority of HER 2+ patients received biological therapy and more patients underwent breast conservation surgery. More patients had LN− disease and were over 50 years at age, presumably as a result of improved breast screening uptake. Almost all (98%) patients with ER+ breast cancer received endocrine treatment.

Median follow-up was 68.25 months (5.7 years). Eighty per cent (*n*=364) patients were alive and well, 7% (*n*=31) had died as a result of breast cancer and 9% (*n*=42) had died from other causes. Four per cent (*n*=19) were alive with documented evidence of breast cancer recurrence; therefore, 11% (*n*=50) had a breast cancer-specific event.

Combined endocrine receptor classification in this cohort was associated with highly significant differences in DFS between CER-negative, CER impaired and CER high groups ([Figure 3A](#fig3){ref-type="fig"}). There was no significant difference in outcome between ER low and ER− ([Figure 3B](#fig3){ref-type="fig"}) or PR low and PR− ([Figure 3C](#fig3){ref-type="fig"}). The CER was a more powerful predictor of DFS than either the ER or PR. In multivariate analysis comparing the three factors, the CER classification was independently significant, CER-negative HR 6.416 (CI: 3.129--13.157; *P*=3.903 × 10^−7^) and CER impaired HR 2.627 (CI: 1.327--5.202; *P=*0.006). In multivariate analysis that included grade, tumour size and LN (HER2 was not included as this was not significantly associated with poor outcome as most HER2+ patients received biological therapy), the CER was independently significant in the validation cohort, including ER+ subgroup (*n*=398) ([Table 2](#tbl2){ref-type="table"}). The CER was a more powerful predictor of DFS than grade and tumour size ([Table 2](#tbl2){ref-type="table"}). Tumour size, grade and LN were independently significant for DFS as expected when included in multivariate analysis without CER (data not shown).

Discussion
==========

The CER is economical and an easily reproducible algorithm using well-validated routinely tested biomarkers. In the derivation study for patients with early breast cancer, the CER was observed to be a better predictor of DFS and BCSS than either ER or PR alone. In addition, the CER is independently significant in multivariate analysis when combined with grade, LN status and tumour size. These findings were validated in a separate, modern cohort of early breast cancer patients.

Semiquantitative IHC is the near universal choice of tumour hormone (ER and PR) receptor testing. Despite its widespread use there have been a number of controversies in recent years regarding hormone testing.

Immunohistochemistry is a semiquantitative technique and preanalytical, analytical and postanalytical factors can influence the results and result in test variation ([@bib1]). In the derivation study, expression levels of both receptors were centrally tested to avoid testing variation. The validation study used the Allred scores from the pathology reports. The receptor testing had been performed in CPA accredited laboratories and represent 'real-world\' data.

Immunohistochemistry assays of ER and PR are limited to determining whether the receptors are present in tumour cells and providing some information on the levels of ER and PR in the tumour. The primary purpose of evaluating the ER and/or PR status for individual patients is to predict whether they will respond to endocrine therapy. For the purposes of selecting endocrine therapy, it is the hormone receptor status that is primarily important. It is notable, however, that 6% of patients of ER− patients were reclassified as CER impaired (ER−/PR+) in the derivation cohort and 1% in the validation cohort, suggesting that the CER categorisation will ensure more patients with hormone receptor-positive disease will be considered eligible for endocrine treatment.

The categorisation should be clinically useful in the context of guiding adjuvant chemotherapy. Importantly, in both cohorts a substantial number of patients with high Allred ER scores were reclassified as impaired using the CER. There is an open question regarding the importance of quantifying hormone receptor expression level by IHC. [@bib10] compared various methods of scoring ER and PR, involving percentage ranges, intensity, both summated and as a product and concluded that the 'any-or-none\' method was just as good at prediction and simpler. Certainly within our own study, the level of ER independently when analysed as negative, low and high did not have a linear relationship with outcome. However, when analysed as the combined endocrine receptor, a direct proportional benefit with outcome and level of receptors was identified. Higher amounts of hormone receptor levels as determined by IHC have been associated with improved patient outcomes ([@bib5]; [@bib9]; [@bib2]; [@bib14]; [@bib8]; [@bib22]; [@bib25]; [@bib6]). These studies suggest that patients with higher ER IHC levels will have a higher probability of good outcome, probably due to good response to endocrine therapy. Our study supports that the level of *both* hormone receptors is important for outcome.

While the predictive power of the ER is undisputed, the predictive power and clinical utility of PR is more controversial ([@bib19]; [@bib12]). Since 2009 the UK National Institute of Clinical Excellence (NICE) no longer recommends PR measurement in routine pathological assessment of early breast cancer ([@bib18]). A number of studies have, however, reported the prognostic power of PR ([@bib24]; [@bib3]; [@bib21]; [@bib15]). Our results are in keeping these studies demonstrating improved outcome in ER+/PR+ breast cancer and support the value of PR measurement in breast cancer patients.

The aim of this study was simple, and combining the ER and PR will be more informative in terms of outcome than either independently. Our working hypothesis is that ER and PR should not be considered alone, both are required and semiquantitative IHC ER and PR scores together may represent a surrogate 'snap shot\' of functional hormone receptor crosstalk. The importance of ER and PR being functionally linked through complex crosstalk has recently been defined ([@bib15]). To our knowledge, we are the first study to report a combined ER and PR IHC. This was a retrospective study and relatively small in terms of patient numbers. We would urge for further testing and application in larger cohorts from different centres to validate this score. The cutoffs applied were based on consensus opinion of what is considered high and low receptor expression of ER and PR ([@bib11]), and supported statistically to define the CER categories. Importantly, the cutoffs were robust in the validation cohort.

In conclusion, the CER is a more powerful predictor of patient outcome than either the ER or PR alone and is a simple and economical method to identify risk in ER+ early breast cancer.
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![**Determination of the cutoffs for the CER. Kaplan--Meier plots were constructed for all possible CER values 0, 0.5, 1, 1.5 and 2.**The outcome is 5-year DFS.](bjc2016206f1){#fig1}

![**Kaplan--Meier plots in the derivation study.** Five-year DFS was plotted according to the CER scores (**A**), ER scores (**B**) or PR scores (**C**). Breast cancer-specific survival at 15 years was plotted according to CER scores (**D**), ER scores (**E**) or PR scores (**F**). Hi=high; imp=impaired; neg=negative.](bjc2016206f2){#fig2}

![**Kaplan--Meier plots in the validation study.**Five-year DFS was plotted according to the CER scores (**A**), ER scores (**B**) or PR scores (**C**). Hi=high; imp=impaired; neg=negative.](bjc2016206f3){#fig3}

###### Characteristics of the derivation study population

                           **Total**   **CER**~**neg**~   **CER**~**imp**~   **CER**~**hi**~
  ------------------------ ----------- ------------------ ------------------ -----------------
  **Age (years)**                                                            
  \<50                     144 (29)    63 (37)            43 (23)            38 (27)
  ⩾50                      359 (71)    109 (63)           146 (77)           104 (73)
  **Grade**                                                                  
  1                        93 (18)     3 (2)              51 (27)            39 (27)
  2                        217 (43)    33 (19)            108 (57)           76 (53)
  3                        191 (38)    134 (78)           30 (16)            27 (19)
  Unknown                  2 (\<1)     2 (1)                                  
  **Lymph node**                                                             
  0                        287 (57)    95 (55)            109 (58)           83 (58)
  1--3                     129 (26)    39 (23)            52 (28)            38 (27)
  \>3                      81 (16)     37 (21)            26 (14)            18 (13)
  Unknown                  6 (1)       1 (\<1)            2 (\<1)            3 (2)
  **Size (mm)**                                                              
  \<20                     297 (59)    83 (49)            121 (64)           93 (66)
  20--50                   189 (38)    81 (47)            62 (33)            46 (32)
  \>50                     16 (3)      7 (4)              6 (3)              3 (2)
  Unknown                  1 (\<1)     1 (\<1)                                
  **ER Allred score**                                                        
  \<3                      184 (37)    172 (100)          12 (6)              
  3--5                     56 (11)                        56 (30)             
  6--8                     263 (52)                       121 (64)           142 (100)
  **PR Allred score**                                                        
  \<3                      281 (56)    172 (100)          109 (58)            
  3--5                     57 (11)                        57 (30)             
  6--8                     165 (33)                       23 (12)            142 (100)
  **HER2**                                                                   
  Positive                 76 (15)     51 (30)            16 (9)             9 (6)
  Negative                 417 (83)    117 (68)           169 (89)           131 (92)
  Unknown                  10 (2)      4 (2)              4 (2)              2 (2)
  **Surgical operation**                                                     
  Mastectomy               322 (64)    105 (61)           125 (66)           92 (65)
  Conservation             181 (36)    67 (39)            64 (34)            50 (35)
  **Endocrine therapy**                                                      
  Yes                      368 (73)    69 (40)            170 (90)           129 (91)
  No                       127 (25)    100 (58)           16 (8)             11 (8)
  Unknown                  8 (2)       3 (2)              3 (2)              2 (1)
  **Chemotherapy**                                                           
  Yes                      208 (42)    116 (67)           49 (26)            43 (30)
  No                       292 (58)    55 (32)            138 (73)           99 (70)
  Unknown                  3 (\<1)     1 (\<1)            2 (1)               

Abbreviations: CER=combined endocrine receptor; ER=oestrogen receptor; HER2=human epidermal growth factor receptor 2; hi=high; imp=impaired; neg=negative; PR=progesterone receptor.

For the derivation population study, patient and tumour characteristics in the column titled 'total\' are recategorised according to the CER classification.

###### Multivariate Cox analysis for 5-year DFS and BCSS in the derivation and validation cohorts

                                   **Hazard ratio (CI)**    **Significance**
  -------------------------------- ----------------------- ------------------
  **Derivation cohort**                                    
  **5-year DFS**                                                    
   Lymph node                      1.895 (1.453--2.472)       *P*=0.00005
   Grade                           1.560 (1.001--2.431)        *P*=0.050
   Size                            1.380 (0.918--2.173)        *P*=0.121
   CER~neg~                        4.441 (1.895--10.411)       *P*=0.001
   CER~imp~                        2.869 (1.240--6.639)        *P*=0.014
   HER2+                           1.676 (1.004--2.798)        *P*=0.048
  **BCSS**                                                          
   Lymph node                      1.833 (1.428--2.353)       *P*=0.000002
   Grade                           1.504 (1.026--2.203)        *P*=0.036
   Size                            1.711 (1.196--2.448)        *P*=0.003
   CER~neg~                        2.024 (1.065--3.848)        *P*=0.031
   CER~imp~                        1.788 (0.974--3.283)        *P*=0.061
   HER2+                           1.182 (0.717--1.948)        *P*=0.511
  **5-year DFS in ER+ patients**                                    
   Lymph node                      2.027 (1.281--3.209)        *P*=0.003
   Grade                           1.646 (0.899--3.012)        *P*=0.106
   Size                            1.208 (0.639--2.35)         *P*=0.561
   CER~imp~                        2.469 (1.049--5.810)        *P*=0.038
   PR~neg~                         0.956 (0.409--2.236)        *P*=0.917
   HER2+                           4.160 (1.803--9.603)        *P*=0.001
  **BCSS ER+ patients**                                             
   Lymph node                      2.070 (1.406--3.049)        *P*=0.0002
   Grade                           1.825 (1.167--2.855)        *P*=0.008
   Size                            1.723 (1.167--2.806)        *P*=0.029
   CER~imp~                        1.946 (1.054--3.596)        *P*=0.033
   PR~neg~                         0.928 (0.464--1.858)        *P*=0.833
   HER2+                           1.535 (0.644--3.629)        *P*=0.329
  **Validation cohort**                                    
  **DFS**                                                           
   Lymph node                      1.818 (1.282--2.579)        *P=0.001*
   Grade                           1.266 (0.731--2.192)        *P*=0.400
   Size                            1.416 (0.825--2.428)        *P*=0.207
   CER~neg~                        5.722 (2.727--12.003)      *P*=0.000004
   CER~imp~                        2.431 (1.196--4.941)        *P*=0.014
  **DFS in ER+ patients**                                           
   Lymph node                      2.388 (1.554--3.671)       *P*=0.00007
   Grade                           1.445 (0.805--2.594)        *P*=0.218
   Size                            1.299 (0.680--2.480)        *P*=0.428
   CER~imp~                        2.096 (1.010--4.351)        *P*=0.047
   PR~neg~                         0.763 (0.299--1.948)        *P*=0.571

Abbreviations: BCSS=breast cancer-specific survival; CER=combined endocrine receptor; CI=confidence interval; DFS=disease-free survival; ER=oestrogen receptor; HER2+=human epidermal growth factor receptor 2-positive; imp=impaired; neg=negative; PR=progesterone receptor.

###### Characteristics of the validation study population

                           **Total**   **CER**~**neg**~   **CER**~**imp**~   **CER**~**hi**~
  ------------------------ ----------- ------------------ ------------------ -----------------
  **Age (years)**                                                            
  \<50                     68 (15)     15 (27)            18 (12)            35 (14)
  ⩾50                      387 (85)    40 (73)            130 (88)           217 (86)
  **Grade**                                                                  
  1                        77 (17)                        22 (15)            55 (22)
  2                        209 (46)    5 (9)              66 (45)            138 (55)
  3                        168 (37)    50 (91)            60 (40)            58 (23)
  Unknown                  1 (\<1)                                           1 (\<1)
  **Lymph node**                                                             
  0                        311 (68)    36 (66)            94 (64)            181 (72)
  1--3                     97 (21)     11 (20)            31 (21)            55 (22)
  \>3                      46 (10)     8 (14)             23 (15)            15 (6)
  Unknown                  1 (\<1)                                           1 (\<1)
  **Size (mm)**                                                              
  \<20                     254 (56)    18 (33)            74 (51)            162 (64)
  20--50                   176 (39)    35 (64)            61 (41)            80 (32)
  \>5                      13 (3)      2 (3)              8 (5)              3 (1)
  Unknown                  12 (3)                         5 (3)              7 (3)
  **ER Allred score**                                                        
  \<3                      57 (12)     55 (100)           2 (1)               
  3--5                     21 (5)                         21 (14)             
  6--8                     377 (83)                       125 (85)           252 (100)
  **PR Allred score**                                                        
  \<3                      111 (24)    55 (100)           56 (38)             
  3--5                     90 (20)                        90 (61)             
  6--8                     254 (56)                       2 (1)              252 (100)
  **HER2**                                                                   
  Positive                 70 (15)     18 (33)            35 (24)            17 (7)
  Negative                 382 (84)    37 (67)            111 (75)           234 (93)
  Unknown                  3 (\<1)                        2 (1)              1 (\<1)
  **Surgical operation**                                                     
  Mastectomy               131 (29)    24 (44)            44 (30)            63 (25)
  Conservation             324 (72)    31 (56)            104 (70)           189 (75)
  **Endocrine therapy**                                                      
  Yes                      392 (86)    2 (4)              140 (95)           250 (99)
  Tamoxifen                184 (40)                       57 (39)            127 (50)
  AI                       138 (30)    2 (4)              57 (39)            79 (31)
  Early switch             46 (10)                        14 (9)             32 (12)
  Late switch              24 (5)                         12 (8)             12 (5)
  No                       63 (14)     53 (96)            8 (5)              2 (\<1)
  **Chemotherapy**                                                           
  Yes                      166 (37)    40 (73)            59 (40)            67 (27)
  No                       289 (63)    15 (27)            89 (60)            185 (73)
  **Biological therapy**                                                     
  Yes                      50 (11)     14 (25)            24 (16)            12 (5)
  No                       405 (89)    41 (75)            124 (84)           240 (95)

Abbreviations: AI=aromatase inhibitor; CER=combined endocrine receptor; ER=oestrogen receptor; HER2=human epidermal growth factor receptor 2; hi=high; imp=impaired; neg=negative; PR=progesterone receptor.

For the validation population study, patient and tumour characteristics in the column titled 'total\' are recategorised according to the CER classification. Patients received endocrine therapy in the form of tamoxifen monotherapy, AI monotherapy, early switch within 5 years AI-tamoxifen or *vice versa* and extended switch, 5 years on AI switched to tamoxifen or *vice versa*.
